Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7506903 | 0.99 | KMT2A (0.56) | KMT2APABPC1ATMALDH1A1CYP1A2 | |
| Bromide SCHEMBL11256908 | 0.84 | NAAA (0.63) | KMT2APABPC1ATMALDH1A1CYP1A2 | |
| SCHEMBL7506380 | 0.83 | HSP90AA1 (0.43) | KMT2APABPC1ATMALDH1A1CYP2D6 | |
| Bromide SCHEMBL1194049 | 0.83 | KMT2A (0.64) | KMT2APABPC1ATMALDH1A1CYP1A2 | |
| Bromide SCHEMBL1193999 | 0.83 | GLA (0.58) | KMT2APABPC1ATMALDH1A1CYP1A2 | |
| Bromide SCHEMBL7113062 | 0.83 | KDM4E (0.44) | KMT2APABPC1ATMALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7048253 | 0.82 | HSP90AA1 (0.45) | ATMALDH1A1CYP2D6LMNAPOLB | |
| Hydrochloric Acid SCHEMBL7051973 | 0.82 | HSP90AA1 (0.67) | KMT2AALDH1A1CYP1A2ADRB2CYP2D6 | |
| SCHEMBL6225837 | 0.81 | GLA (0.56) | KMT2APABPC1ATMALDH1A1CYP1A2 | |
| SCHEMBL7576220 | 0.81 | KDM4E (0.45) | KMT2AALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | claimed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | claimed |
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | disclosed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | disclosed |
| EP-1220843-A1 | PYRIDINIUM DERIVATIVES FOR THE TREATMENT OF DIABETIC AND AGING-RELATED VASCULAR COMPLICATIONS | Torrent Pharmaceuticals Ltd (IN) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025209-A1 | PYRIDINIUM DERIVATIVES FOR THE TREATMENT OF DIABETIC AND AGING-RELATED VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | PNPO, PRDX5, PLPBP | ACHE 110/4885KMT2A 3459/4885PABPC1 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.